XSHG
600129
Market cap1.11bUSD
Oct 09, Last price
13.97CNY
1D
4.10%
1Q
-15.74%
Jan 2017
-18.54%
Name
Chongqing Taiji Industry(Group)Co.
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Chongqing Taiji Industry (Group) Co.,Ltd operates as a pharmaceutical enterprise, conducting business both within China and across international markets. The company focuses on the research, development, manufacturing, and distribution of traditional Chinese medicines and various health products. Its offerings are available in a wide array of formats, including tablets, oral liquids, syrups, dripping pills, granules, capsules, tinctures, and powders. The product line addresses a comprehensive range of health conditions and therapeutic areas. These include disorders of the digestive and respiratory systems, cardiovascular and cerebrovascular ailments, pediatric and gynecological health, systemic anti-infective agents and antibiotics, pain relief medications, orthopedic treatments, remedies for colds and coughs, and drugs for the endocrine and nervous systems. The firm's headquarters are situated in Chongqing, China.
Key people
Zhiyang Nie
Director · since 2012
Yonghong Yuan
General Manager, Director · since 2016
Kai Zhang
Director · since 2012
Independent Director · since 2009
De Shi
Independent Director · since 2008
Independent Director · since 2009
Guoyue Zhong
Independent Director · since 2012
Jianbi Zhu
Independent Director · since 2008
Headquarters & legal address
重庆市涪陵区太极大道1号
涪陵区, CQ 100000
CN
涪陵区, CQ 100000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||